Last reviewed · How we verify
NCT03383042
Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of JP-1366 Oral Administration in Healthy Male Subjects
Phase 1 trial testing Cohort 1 (JP-1366 A mg) in Anti-Ulcer Agents in 115 participants. Completed in 5 April 2019.
23 November 2018
Quick facts
| Lead sponsor | Jeil Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 115 |
| Start date | 22 December 2017 |
| Primary completion | 23 November 2018 |
| Estimated completion | 5 April 2019 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Cohort 1 (JP-1366 A mg)
- Cohort 2 (JP-1366 B mg)
- Cohort 3 (JP-1366 C mg)
- Cohort 4 (JP-1366 D mg) — full drug profile →
- Cohort 5 (JP-1366 E mg) — full drug profile →
- Cohort 6 (JP-1366 F mg)
- Cohort 7 (JP-1366 G mg) — full drug profile →
- Cohort 8 (JP-1366 H mg) — full drug profile →
- Cohort 9 (JP-1366 I mg) — full drug profile →
Conditions studied
- Anti-Ulcer Agents — all drugs for Anti-Ulcer Agents →
Sponsor
Jeil Pharmaceutical Co., Ltd. — full company profile →
Who can join
Adults 19 to 50, male only, with Anti-Ulcer Agents. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Clinical trial to investigate the safety, tolerability and pharmacokinetics and pharmacodynamics of JP-1366 oral administration in healthy male subjects
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03383042
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Jeil Pharmaceutical Co., Ltd. trials
Trials by the same sponsor.
- NCT07115706 — JAQBO® Tab. 20 mg(Zastaprazan Citrate) in Erosive GERD · not yet recruiting
- NCT06952855 — Observationa Study is a Prospective and Multi-institutional Observational Study. · completed
- NCT06431399 — To Evaluate the Safety, Pharmacokinetic Characteristics and the Effect of Food After Administration of JLP-2004 · Phase 1 · recruiting
- NCT06169059 — To Evaluate the Safety and Pharmacokinetic Characteristics After Multiple Administration of JC-013 and JLP-2004 · Phase 1 · completed
- NCT06165965 — To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008 · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03383042 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jeil Pharmaceutical Co., Ltd.
- Last refreshed: 22 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03383042.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing